Dr. Richard Isaacson was featured in The Wall Street Journal discussing the growing interest in GLP-1 medications among amateur athletes seeking to optimize their health and performance. The article explores the emerging trend of microdosing weight-loss medications, the potential benefits and risks, and the unanswered questions surrounding their use in otherwise healthy individuals.

Drawing on his clinical experience, Dr. Isaacson described how he has carefully evaluated low-dose GLP-1 therapy for select patients:

“We tried to see what was the minimal dose that he could tolerate without losing any more weight.”

The article also highlights Dr. Isaacson’s own experience studying the effects of GLP-1 therapy on health optimization, emphasizing the need for individualized care and continued research as these medications are explored beyond their traditional use.

Read the full Wall Street Journal article to learn more about the evolving role of GLP-1 therapies in health, performance, and longevity.